BG Medicine obtains CE Mark and launches automated BGM Galectin-3 test BG Medicine announced that the first automated version of the BGM Galectin-3 blood test has obtained a CE Mark, an important step in the company's commercial strategy. The BGM Galectin-3 test will be distributed through bioMérieux's VIDAS immunoassay platform which includes about 27,000 installed instruments worldwide. bioMérieux is one of four diagnostic instrument manufacturers partnering with BG Medicine to commercialize automated versions of the BGM Galectin-3 test, and the first to obtain a CE Mark. bioMérieux is preparing a phased launch of the test in Europe and in certain other territories that recognize the CE Mark.
News For BGMD From The Last 14 Days
Check below for free stories on BGMD the last two weeks.